Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ibrance 75mg capsules
0801050CBBBAAAA
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
|
Ibrance 75mg tablets
0801050CBBBAFAF
|
Ibrance | Palbociclib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 140mg capsules
0801050BSAAAAAA
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 140mg tablets
0801050BSAAABAB
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 280mg tablets
0801050BSAAACAC
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 420mg tablets
0801050BSAAADAD
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Ibrutinib 560mg tablets
0801050BSAAAEAE
|
Ibrutinib | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Iclusig 15mg tablets
0801050BQBBAAAA
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Iclusig 30mg tablets
0801050BQBBACAC
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Iclusig 45mg tablets
0801050BQBBABAB
|
Iclusig | Ponatinib | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 10mg capsules
0801020P0AAADAD
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 10mg powder for solution for injection vials
0801020P0AAABAB
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 10mg/10ml solution for injection vials
0801020P0AAAFAF
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 25mg capsules
0801020P0AAAEAE
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg capsules
0801020P0AAACAC
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg powder for solution for injection vials
0801020P0AAAAAA
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Idarubicin 5mg/5ml solution for injection vials
0801020P0AAAGAG
|
Idarubicin hydrochloride | Idarubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Ifosfamide 1g powder for solution for injection vials
0801010N0AAABAB
|
Ifosfamide | Ifosfamide | Malignant Disease and Immunosuppression | No data available |
|
Ifosfamide 2g powder for solution for injection vials
0801010N0AAACAC
|
Ifosfamide | Ifosfamide | Malignant Disease and Immunosuppression | No data available |
|
Ilaris 150mg powder for solution for injection vials
0802040ACBBAAAA
|
Ilaris | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Ilaris 150mg/1ml solution for injection pre-filled pens
0802040ACBBACAC
|
Ilaris | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Ilaris 150mg/1ml solution for injection vials
0802040ACBBABAB
|
Ilaris | Canakinumab | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 140mg capsules
0801050BSBBAAAA
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 140mg tablets
0801050BSBBABAB
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 280mg tablets
0801050BSBBACAC
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.